van der Meer, Dennis
Hartman, Catharina A.
Pruim, Raimon H. R.
Mennes, Maarten
Heslenfeld, Dirk
Oosterlaan, Jaap
Faraone, Stephen V.
Franke, Barbara
Buitelaar, Jan K.
Hoekstra, Pieter J.
Funding for this research was provided by:
National Institutes of Health (R01MH62873)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (1750102007010)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (433-09-242)
Seventh Framework Programme (278948, 602450, 602805)
Horizon 2020 (643051)
Article History
First Online: 13 October 2016
Compliance with ethical standards
:
: This work was supported by National Institutes of Health (NIH) Grant R01MH62873 (to Stephen V. Faraone), Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO) Large Investment Grant 1,750,102,007,010 and NWO Brain & Cognition an Integrative Approach grant (433–09-242) (to Jan. Buitelaar), and grants from Radboud University Nijmegen Medical Center, University Medical Center Groningen and Accare, and VU University Amsterdam. The research leading to these results also received funding from the European Community’s Seventh Framework Programme (FP7/2007–2013) under grant agreement numbers 278,948 (TACTICS), 602,450 (IMAGEMEND) and n° 602,805 (Aggressotype), and from the European Community’s Horizon 2020 Programme (H2020/2014–2020) under grant agreement n° 643,051 (MiND). Barbara Franke is supported by a Vici grant from NWO (grant number 016–130-669). In addition, Jan. Buitelaar and Barbara Franke are supported by a grant for the ENIGMA Consortium (grant number U54 EB020403) from the BD2K Initiative of a cross-NIH partnership.
: <b>Barbara Franke</b> has received a speaker fee from Merz. <b>Pieter J. Hoekstra</b> has received an unrestricted research grant from Shire and has been member of the advisory boards of Shire and Eli Lilly. <b>Jaap Oosterlaan</b> has received an unrestricted investigator initiated research grant from Shire pharmaceuticals. <b>Jan. K. Buitelaar</b> has been in the past 3 years a consultant to / member of advisory board of / and/or speaker for Janssen Cilag BV, Eli Lilly, Shire, Novartis, Roche and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. In the past year, <b>Stephen V. Faraone</b> received income, travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, Alcobra, VAYA Pharma, and SynapDx and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. Dr. Faraone receives royalties from books published by Guilford Press: <i>Straight Talk about Your Child’s Mental Health</i> and Oxford University Press: <i>Schizophrenia: The Facts</i>. <b>All other authors</b> report no competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.This article does not contain any studies with animals performed by any of the authors.